← Back to patent-cliff list
Ropivacaine Extended-Release Microspheres (Yichang Humanwell)
Tier C — Watch / tradeRopivacaine Extended-Release Microspheres (Yichang Humanwell)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Sodium channels
Indications (approved)：Postoperative pain, Pain
Regional status
US
-
EU
-
China
Phase III
2026-03-31
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ropivacaine Extended-Release Microspheres (Yichang Humanwell)?
Approved indications include: Postoperative pain, Pain.
When does the Ropivacaine Extended-Release Microspheres (Yichang Humanwell) patent expire?
No public expiry year is available for Ropivacaine Extended-Release Microspheres (Yichang Humanwell) yet; this page updates once verified.
How do I get a quote for Ropivacaine Extended-Release Microspheres (Yichang Humanwell) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29